Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). It is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.
Market Cap:858.3M; Shares Outstanding:18.5M; Short Interest: 2.07%; Q3 2019(9/30/19): Cash 32.95M. Loss 10.71M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 33，no change
Shares hold: 2395.9k shares. no change
shares% hold: 12.94%，no change